Cargando…

Trimeric protein vaccine based on Beta variant elicits robust immune response against BA.4/5-included SARS-CoV-2 Omicron variants

The current Coronavirus Disease 2019 (COVID-19) pandemic, induced by newly emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variants, posed great threats to global public health security. There is an urgent need to design effective next‑generation vaccines against Omicro...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Cai, Chen, Li, Yang, Jingyun, Chen, Zimin, Lei, Hong, Hong, Weiqi, Song, Xiangrong, Yang, Li, Li, Jiong, Wang, Wei, Shen, Guobo, Lu, Guangwen, Wei, Xiawei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Nature Singapore 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998262/ https://www.ncbi.nlm.nih.gov/pubmed/36894743 http://dx.doi.org/10.1186/s43556-023-00121-7

Ejemplares similares

A recombinant spike‐XBB.1.5 protein vaccine induces broad‐spectrum immune responses against XBB.1.5‐included Omicron variants of SARS‐CoV‐2
por: He, Cai, et al.
Publicado: (2023)

Spike protein of SARS‐CoV‐2 Omicron (B.1.1.529) variant has a reduced ability to induce the immune response
por: He, Cai, et al.
Publicado: (2022)

A self-assembled trimeric protein vaccine induces protective immunity against Omicron variant
por: He, Cai, et al.
Publicado: (2022)

Cationic crosslinked carbon dots-adjuvanted intranasal vaccine induces protective immunity against Omicron-included SARS-CoV-2 variants
por: Lei, Hong, et al.
Publicado: (2023)

A bivalent recombinant vaccine targeting the S1 protein induces neutralizing antibodies against both SARS‐CoV‐2 variants and wild‐type of the virus
por: He, Cai, et al.
Publicado: (2021)

Intranasal administration of a recombinant RBD vaccine induces long-term immunity against Omicron-included SARS-CoV-2 variants
por: Lei, Hong, et al.
Publicado: (2022)

Heterologous vaccination with subunit protein vaccine induces a superior neutralizing capacity against BA.4/5‐included SARS‐CoV‐2 variants than homologous vaccination of mRNA vaccine
por: Peng, Dandan, et al.
Publicado: (2023)

Low levels of neutralizing antibodies against XBB Omicron subvariants after BA.5 infection
por: Yang, Jingyun, et al.
Publicado: (2023)

SARS‐CoV‐2 Omicron variant: Characteristics and prevention
por: He, Xuemei, et al.
Publicado: (2021)

Biparatopic antibody BA7208/7125 effectively neutralizes SARS-CoV-2 variants including Omicron BA.1-BA.5
por: Wang, Yanqun, et al.
Publicado: (2023)

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
por: Rössler, Annika, et al.
Publicado: (2022)

Cationic nanocarriers as potent adjuvants for recombinant S-RBD vaccine of SARS-CoV-2
por: Lei, Hong, et al.
Publicado: (2020)

Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies
por: Zhou, Hao, et al.
Publicado: (2022)

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
por: Cao, Yunlong, et al.
Publicado: (2022)

Real-world evaluation of bebtelovimab effectiveness during the period of COVID-19 Omicron variants, including BA.4/BA.5
por: Molina, Kyle C., et al.
Publicado: (2023)

Reduced sensitivity of SARS-CoV-2 Omicron variant to antibody neutralization elicited by booster vaccination
por: Yu, Xiaoqi, et al.
Publicado: (2022)

Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection
por: Khan, Khadija, et al.
Publicado: (2022)

Thrombosis and lymphocyte subsets of COVID-19 omicron BA.2 variant patients with cancer
por: Yin, Jiaxin, et al.
Publicado: (2022)

Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
por: Yu, Jingyou, et al.
Publicado: (2022)

Case report: Severe acute hepatitis in a 22-month-old Chinese boy with Omicron sub-variant BA.2.38
por: Chen, Xinying, et al.
Publicado: (2022)

Potent and broad neutralization of SARS-CoV-2 variants of concern (VOCs) including omicron sub-lineages BA.1 and BA.2 by biparatopic human VH domains
por: Chen, Chuan, et al.
Publicado: (2022)

COVID-19 Adenoviral Vector Vaccination Elicits a Robust Memory B Cell Response with the Capacity to Recognize Omicron BA.2 and BA.5 Variants
por: Fryer, Holly A., et al.
Publicado: (2023)

SARS‐CoV‐2 Omicron variant: Immune escape and vaccine development
por: Ao, Danyi, et al.
Publicado: (2022)

A spike-trimer protein-based tetravalent COVID-19 vaccine elicits enhanced breadth of neutralization against SARS-CoV-2 Omicron subvariants and other variants
por: Wang, Rui, et al.
Publicado: (2022)

Vaccine- and Breakthrough Infection-Elicited Pre-Omicron Immunity More Effectively Neutralizes Omicron BA.1, BA.2, BA.4 and BA.5 Than Pre-Omicron Infection Alone
por: Santos da Silva, Eveline, et al.
Publicado: (2023)

Comparable Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
por: Yu, Jingyou, et al.
Publicado: (2022)

Influence of vaccination and prior immunity on the dynamics of Omicron BA.1 and BA.2 sub-variants
por: Dimeglio, Chloé, et al.
Publicado: (2022)

Emergence of Omicron BA.1 and BA.2 variants and concern over vaccine breakthrough infection
por: Sukaina, Mahnoor, et al.
Publicado: (2022)

Emergence of omicron variant's sublineages BA.4 and BA.5: risks assessment and possible countermeasures
por: Dhawan, Manish, et al.
Publicado: (2022)

Omicron BA.2 (B.1.1.529.2): high potential to becoming the next dominating variant
por: Chen, Jiahui, et al.
Publicado: (2022)

Omicron BA.2 (B.1.1.529.2): high potential to becoming the next dominating variant
por: Chen, Jiahui, et al.
Publicado: (2022)

Comparison of the clinical and virological characteristics of SARS-CoV-2 Omicron BA.1/BA.2 and omicron BA.5 variants: A prospective cohort study
por: Kang, Sung-Woon, et al.
Publicado: (2023)

Evolutionary analysis of Omicron variant BF.7 and BA.5.2 pandemic in China
por: Sun, Yamin, et al.
Publicado: (2023)

An mRNA vaccine with broad-spectrum neutralizing protection against Omicron variant sublineages BA.4/5 -included SARS-CoV-2
por: Sang, Ye, et al.
Publicado: (2022)

Omicron subvariants escape antibodies elicited by vaccination and BA.2.2 infection
por: Yao, Lin, et al.
Publicado: (2022)

Structural Basis for Human Receptor Recognition by SARS-CoV-2 Omicron Variant BA.1
por: Geng, Qibin, et al.
Publicado: (2022)

Author Correction: Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection
por: Khan, Khadija, et al.
Publicado: (2022)

S19W, T27W, and N330Y mutations in ACE2 enhance SARS-CoV-2 S-RBD binding toward both wild-type and antibody-resistant viruses and its molecular basis
por: Ye, Fei, et al.
Publicado: (2021)

The challenges of COVID‐19 Delta variant: Prevention and vaccine development
por: He, Xuemei, et al.
Publicado: (2021)

PIKfyve inhibitors against SARS-CoV-2 and its variants including Omicron
por: Su, Jingyi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6qgtvptv1qbigapnei098uvl2k